Tuesday, May 16, 2017 10:35:39 AM
POSTED ON 5.4.2017
Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan OTC ticker: 1795) today announced that MA of the branded product AclastaR solution for infusion was successfully transferred from Novartis Taiwan to Lotus Pharmaceutical. The acquired product for osteoporosis will be marketed in Taiwan by Lotus.
LOTUS WILL MARKET ACLASTA IN TAIWAN: LOTUS GENERAL MANAGER JEFFERSON WANG AND DR. RONG-SEN YANG FROM DEPARTMENT OF ORTHOPEDIC SURGERY OF NATIONAL TAIWAN UNIVERSITY HOSPITAL EXCHANGED THOUGHTS ON THE THERAPEUTIC AREA
The acquisition of this well-established branded product further strengths Lotus’ branded portfolio in Taiwan particularly in a steadily growing market as osteoporosis. Commenting on the transaction, Jefferson Wang, General Manager of Lotus, said, “The acquisition solidifies our local portfolio and enhances our platform for continued growth across the APAC region. We continue to build our offer in Taiwan to catalyze growth and there will be more new product launches starting 2017.”
C4urself the 1st Ammendment.
Don't assume that i don't know, and i wont assume, that you have no idea.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM